
    
      This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2%
      lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10
      years of age presenting to a pediatric emergency department with an acute frontal migraine
      headache. Excluded populations include those with sickle cell, concern for CNS infection
    
  